Differential pattern of brain‐specific CSF proteins tau and amyloid‐beta in Parkinsonian syndromes |
| |
| Authors: | Sigurd D Süssmuth MD Ingo Uttner PhD Bernhard Landwehrmeyer MD Elmar H Pinkhardt MD Johannes Brettschneider MD Axel Petzold MD PhD Bernd Kramer MD Jörg B Schulz MD Christian Palm MD Markus Otto MD Albert C Ludolph MD Jan Kassubek MD Hayrettin Tumani MD |
| |
| Institution: | 1. Department of Neurology, University of Ulm, Ulm, Germany;2. Deparment of Neuroimmunology, Institute of Neurology, Queen Square, London, UK;3. Department of Neurodegeneration and Restorative Research, Center for Neurological Medicine, University of G?ttingen, G?ttingen, Germany |
| |
| Abstract: | To evaluate cerebrospinal fluid (CSF) proteins reflecting processes of neurodegeneration and glial activation in progressive supranuclear palsy (PSP; Richardson's syndrome, n = 20; PSP‐Parkinsonism, n = 7) and multiple system atrophy (MSA, n = 25), we analyzed tau, phosphorylated tau, amyloid‐beta1–42 (Aβ1–42), Aβ1–40, glial fibrillary acidic protein (GFAP), and CSF routine variables. Individuals with PSP‐Parkinsonism and MSA had elevated tau levels when compared with Richardson's syndrome, Parkinson's disease (PD), and age‐matched controls (P ≤ 0.001). Ratios of P‐tau/T‐tau were significantly different in Parkinsonian syndromes. CSF Aβ1–42 was decreased only in patients with Richardson's syndrome. In a subset of Parkinsonian syndromes, we found elevated GFAP concentrations and increased CSF/serum albumin ratios. There were no correlations between biomarker concentrations and clinical scores in any of the diseases. In conclusion, this preliminary data show that changes in CSF tau and Aβ1–42 may indicate different protein processing in PSP patients and might, therefore, be relevant in the differentiation of PSP subtypes. © 2010 Movement Disorder Society |
| |
| Keywords: | cerebrospinal fluid biomarker progressive supranuclear palsy Richardson's syndrome PSP‐P multiple system atrophy |
|
|
